Floatz logo

Gefetinib

Thyroid Gland Medullary Carcinoma

National Cancer Institute (NCI)N/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Thyroid Gland Medullary Carcinoma cohort.

Asset / SponsorPhaseRating
Tarlatamab
University of Arizona
Phase 2B
Bms-907351
National Cancer Institute (NCI)
Phase 2B
Selpercatinib
Eli Lilly and Company
Phase 2B
Oxodotreotide
M.D. Anderson Cancer Center
Phase 2CCC
Pralsetinib, trans-
Hoffmann-La Roche
Phase 1/2CCC

View all 36 →

Same molecule, other indications

Gefetinib is also rated in:

central nervous system neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
gliosarcomaDormant
BB
Indicative ·
71 / 100
View asset →
lung adenocarcinoma in situDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →